1 Hunter Holmes McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA 23224, USA ; 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Transl Lung Cancer Res. 2016 Apr;5(2):183-9. doi: 10.21037/tlcr.2016.04.05.
There is debate about what is the optimal treatment for operable stage I non-small cell lung cancer (NSCLC). Although surgery has been the standard of care for centuries, recent retrospective and prospective randomized studies indicated that stereotactic ablative radiotherapy (SABR) could be an option for this group of patients with similar survival and less toxicities. However, to change the standard of care, more studies are needed and participating ongoing larger randomized studies is the best approach to resolve this controversy.
对于可手术的 I 期非小细胞肺癌（NSCLC），哪种治疗方法最佳存在争议。尽管手术已成为数百年的治疗标准，但最近的回顾性和前瞻性随机研究表明，立体定向消融放疗（SABR）可能是这组患者的一种选择，其生存情况相似，毒性更小。然而，要改变治疗标准，还需要更多的研究，参与正在进行的更大规模的随机研究是解决这一争议的最佳方法。
